Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler that’s prescribed for COPD. This article covers topics such as side effects, dosage ...

The FDA has approved GlaxoSmithKline’s Trelegy Ellipta inhaler for asthma in adults, adding to its existing use in chronic obstructive pulmonary disease (COPD), stealing a march on rivals ...

So far Trelegy has been launched in 30 countries and continues to roll out, with recent approvals in Japan and China setting up launches in those big markets later this year.

The global dyspnea treatment market, valued at USD 6.31 billion in 2023, is poised for remarkable growth, with projections ...